Today: 27 April 2026

Shan Ahmed Khan

As a journalist focused on finance and the stock market, he delivers fast, reliable, and easy-to-understand coverage of market news.

Tesla stock braces for earnings week after Tesla puts key Autopilot features behind $99-a-month FSD

Tesla stock braces for earnings week after Tesla puts key Autopilot features behind $99-a-month FSD

Tesla has removed Autosteer and some highway driver-assist features from its standard package in the U.S. and Canada, directing buyers to a $99/month Full Self-Driving subscription. The move comes days before Tesla’s Jan. 28 earnings report, as investors watch software revenue and regulatory scrutiny. Shares closed Friday at $449.06, down 0.1%. California’s DMV has warned Tesla over potentially misleading marketing.
25 January 2026
····
Opendoor stock drops 6% into Fed week — what OPEN shares are up against next

Opendoor stock drops 6% into Fed week — what OPEN shares are up against next

Opendoor shares fell 6.4% to $6.01 Friday, with trading volume jumping to 63.7 million ahead of next week’s Federal Reserve rate decision. The drop came as mortgage rates hovered near three-year lows and peers like Zillow and Rocket also slipped. Opendoor will report fourth-quarter earnings on Feb. 26. Investors are watching for Fed signals and housing data due Jan. 27.
25 January 2026
··
Plug Power stock whipsaws near $2.50 as investors brace for Jan. 29 share vote

Plug Power stock whipsaws near $2.50 as investors brace for Jan. 29 share vote

Plug Power shares fell 3.47% to $2.50 Friday, with volume topping 107.9 million ahead of a Jan. 29 shareholder vote on doubling authorized shares and changing voting rules. The company warned it may pursue a reverse stock split if the proposal fails. Plug also reported completion of a 100 MW electrolyzer installation at Galp’s Sines refinery in Portugal. Walmart canceled a warrant for up to 55.3 million Plug shares earlier this month.
25 January 2026
·
ImmunityBio stock tumbles after glioblastoma update; what to watch before Monday

ImmunityBio stock tumbles after glioblastoma update; what to watch before Monday

ImmunityBio shares fell 12.1% to $6.45 Friday after the company previewed new data from its Phase 2 glioblastoma trial, with full results due Jan. 31. The stock traded heavily between $7.88 and $6.43. Median overall survival in the study was “not yet reached” as of Jan. 22, with 19 of 23 patients alive. Investors are watching for more details on durability, safety, and trial design.
25 January 2026
·····
Grab (GRAB) stock near $4.6 as GoTo takeover talks hit a snag — what to watch next week

Grab (GRAB) stock near $4.6 as GoTo takeover talks hit a snag — what to watch next week

Grab Holdings shares closed up 0.7% at $4.58 after reports that its planned takeover of GoTo faced new resistance from state-linked shareholder Telkomsel. Talks reportedly stalled over Telkomsel’s 2% stake, with the carrier unwilling to sell at current prices. Antitrust concerns and draft Indonesian regulations add further uncertainty. Grab and GoTo declined to comment.
25 January 2026
··
Intel stock price tumbles 17% on outlook shock — what to watch before Monday’s open

Intel stock price tumbles 17% on outlook shock — what to watch before Monday’s open

Intel shares fell 17% to $45.07 after the company forecast first-quarter revenue below Wall Street expectations and reported a 4% year-over-year decline in fourth-quarter revenue. The company cited supply constraints in its AI data center chips and warned supply would be tightest in Q1. Nearly 295 million shares traded. CEO Lip-Bu Tan said Intel cannot fully meet demand in the short term.
25 January 2026
·
BigBear.ai stock set for a fresh test Monday as BBAI slips and a dilution vote hangs over shares

BigBear.ai stock set for a fresh test Monday as BBAI slips and a dilution vote hangs over shares

BigBear.ai shares closed Friday down 1.9% at $5.82, with 86.5 million shares traded. Shareholders will vote Feb. 18 on doubling authorized shares to 1 billion, following full conversion of $125 million in convertible notes and a new CargoSeer technology deal. CEO Kevin McAleenan urged approval, citing limited shares left. Voting ends Feb. 17 at 11:59 p.m. ET.
25 January 2026
·
MP Materials stock: what traders are watching after a fresh U.S. rare-earths funding signal

MP Materials stock: what traders are watching after a fresh U.S. rare-earths funding signal

MP Materials shares rose 1.8% to $69.58 Friday ahead of a $1.6 billion U.S. investment package for rare earths expected Monday. The Trump administration plans to acquire a 10% stake in USA Rare Earth, according to sources cited by Reuters. Investors are watching for policy impacts and MP’s next earnings update, set for Feb. 19. The Financial Times reports the deal includes equity, warrants, and loans for mine and magnet factory construction.
25 January 2026
·
Bloom Energy stock price heads into Monday after Friday dip as data centers talk more onsite power

Bloom Energy stock price heads into Monday after Friday dip as data centers talk more onsite power

Bloom Energy shares closed at $144.89 Friday, down 0.5% after a volatile session, but remain up 67% year-to-date. The stock hit a high of $155.87 earlier in the week amid surging interest in onsite power for data centers. Investors await Bloom’s Q4 results on Feb. 5, with focus on data center bookings and margins. Fuel-cell peers showed mixed moves Friday, with Plug Power falling and FuelCell Energy rising.
25 January 2026
·····
Vertical Aerospace stock price (EVTL) slips as Valo New York push meets dilution worries

Vertical Aerospace stock price (EVTL) slips as Valo New York push meets dilution worries

Vertical Aerospace shares fell 2.6% to $5.60 Friday, closing out a week down nearly 7%. The company disclosed an expanded authorized share pool to 1 billion, raising dilution concerns as it pursues funding. Vertical is promoting its Valo eVTOL in New York with Bristow and Skyports. Cash on hand stood at about £69 million ($93 million) as of Dec. 31, 2025, according to preliminary filings.
25 January 2026
···
USA Rare Earth stock faces Monday test after report of $1.6 billion U.S. stake deal

USA Rare Earth stock faces Monday test after report of $1.6 billion U.S. stake deal

USA Rare Earth (USAR.O) shares jumped 9.1% to $24.77 Friday after sources said the U.S. will take a 10% stake in a $1.6 billion deal, with an announcement expected Monday. The government is set to receive 16.1 million shares and warrants for 17.6 million more at $17.17 each. Investors await details on financing terms and possible dilution. The White House and company declined comment.
25 January 2026
··
Joby Aviation stock slips 4% before Wall Street reopens — here’s what investors watch next

Joby Aviation stock slips 4% before Wall Street reopens — here’s what investors watch next

Joby Aviation shares fell 4.2% to $13.93 Friday as small-cap stocks slumped, with the Russell 2000 down 1.8%. The drop comes ahead of the Federal Reserve’s Jan. 27-28 meeting and a wave of major earnings reports. Joby’s next earnings report is set for Feb. 25, with investors watching certification progress and cash burn. Joby recently agreed to buy a $61.5 million Ohio property to expand production.
25 January 2026
··
Antofagasta stock faces Monday test after Chile roadblock strike, Centinela fine ahead of Q4 update

Antofagasta stock faces Monday test after Chile roadblock strike, Centinela fine ahead of Q4 update

Antofagasta shares closed up 1.9% at 3,584 pence Friday, despite striking contractors blocking access to the Zaldivar mine in Chile over the weekend. Chile’s regulator fined Antofagasta Minerals about $775,000 for water-management breaches at Centinela. Copper prices rose, with LME cash settlement at $12,920.50 per ton. Antofagasta will release its Q4 production report Jan. 29.
25 January 2026
·
1 … 152 153 154 155 156 … 584

Stock Market Today

  • Options Traders Reflect on Toughest Lessons Learned
    April 27, 2026, 3:59 PM EDT. Options traders discuss valuable insights gained from difficult experiences in the derivatives market. Trading options-contracts granting the right to buy or sell an asset at a set price-requires understanding complex risks. Many traders highlight the importance of discipline, managing losses, and resisting emotional decisions. These lessons often come after costly mistakes, underlining how quickly volatility and leverage can amplify losses. Industry voices stress education and strategy adjustments as key to survival and success in options trading.

Latest article

Intellia Therapeutics CRISPR Trial Win Puts One-Time HAE Drug On FDA Track

Intellia Therapeutics CRISPR Trial Win Puts One-Time HAE Drug On FDA Track

27 April 2026
Intellia Therapeutics reported its CRISPR drug lonvo-z cut hereditary angioedema attacks by 87% versus placebo in a late-stage trial, with 62% of treated patients attack- and therapy-free over six months. The company has started a rolling U.S. approval application. No serious adverse events were reported. Intellia shares fell 0.9% to $13.51 after initial gains.
U.S. Energy Corp Stock Jumps as $285 Helium Deal Gives Big Sky a Buyer

U.S. Energy Corp Stock Jumps as $285 Helium Deal Gives Big Sky a Buyer

27 April 2026
U.S. Energy Corp. signed a five-year helium sales deal with an unnamed global industrial gas company, securing a buyer for output from its planned Big Sky Carbon Hub in Montana. The contract covers up to 1.2 million cubic feet a month at a fixed $285 per thousand cubic feet, with inflation adjustments starting March 2028. U.S. Energy shares rose 20.8% to $1.12 on heavy volume. The agreement is “take-or-pay,” with the buyer handling pickup at the plant.
Veradermics Stock Jumps After VDPHL01 Hair-Loss Pill Hits Trial Goals

Veradermics Stock Jumps After VDPHL01 Hair-Loss Pill Hits Trial Goals

27 April 2026
Veradermics shares rose 40% Monday after its oral hair-loss drug VDPHL01 met all main goals in a Phase 2/3 trial of 519 men. Patients taking the drug saw average hair count increases of 30.3 to 33.0 hairs per square centimeter over six months, compared to 7.3 for placebo. No treatment-related serious or heart-related adverse events were reported.
Go toTop